Lawrence Wickerham

TL;DR: The observations through eight years are consistent with the findings at five years and that these new findings continue to support the use of lumpectomy in patients with Stage I or II breast cancer, and it is concluded that irradiation reduces the probability of local recurrence of tumor in patients treated with Lumpectomy.

TL;DR: There are no compelling reasons why DCIS may not be treated in a cosmetically acceptable manner by LX, and estimates of the probability of local recurrence or survival suggest that they will not be significantly altered after longer periods of surveillance.

TL;DR: Tamoxifen reduced breast cancer incidence among healthy BRCA2 carriers by 62%, similar to the reduction in incidence of ER-positive breast cancer among all women in the Breast Cancer Prevention Trial.

TL;DR: The incidence as well as annual accrual per patients at risk of bilateral cancers is low; most second cancers, although clinically metachronous, are probably biologically synchronous; a second cancer does not influence the expected survival of patients who develop such an event; and the incidence of contralateral metastases from breast cancer is extremely rare.

TL;DR: Women with breast cancer currently taking part in a randomized clinical trial to determine the efficacy of tamoxifen (20 mg/day) in preventing recurrences should have a thorough baseline ophthalmic evaluation within the first year of initiating tamoxIFen therapy and receive appropriate follow-up evaluations.